Date published: 2025-10-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

MAP-1A Inhibitors

MAP-1A inhibitors belong to a significant class of chemical compounds that exert their effects by modulating the activity of microtubule-associated protein 1A (MAP-1A). Microtubules are essential components of the cytoskeleton, involved in maintaining cell shape, intracellular transport, and cell division. MAP-1A, a protein associated with microtubules, plays a pivotal role in regulating microtubule dynamics, stability, and organization within the cell. The inhibitors targeting MAP-1A are designed to interfere with its function, leading to alterations in microtubule assembly and dynamics. Structurally, MAP-1A inhibitors often possess specific binding motifs that interact with distinct regions of the MAP-1A protein, disrupting its normal interaction with microtubules. By doing so, these inhibitors perturb microtubule polymerization, leading to changes in microtubule length, stability, and arrangement. This can have a cascading effect on various cellular processes, as microtubules are involved in intracellular transport of organelles and molecular cargo, as well as in signaling pathways and cell division. The inhibition of MAP-1A can result in a reconfiguration of the microtubule network, affecting cellular morphology and function. Researchers and scientists are actively investigating the mechanisms and implications of MAP-1A inhibitors in cellular contexts. Understanding how these inhibitors interact with MAP-1A and alter microtubule dynamics can provide insights into the fundamental processes governing cellular structure and function. By shedding light on the intricate interplay between MAP-1A, microtubules, and the cellular environment, this class of compounds opens up avenues for further exploration of cellular biology and molecular pharmacology.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Maytansine

35846-53-8sc-507510
100 mg
$1000.00
(0)

Inhibits microtubule assembly, investigated for targeted drug delivery.